CD274 and neoplasm: Squamous or non-squamous cell locally advanced or metastatic NSCLC; disease progression during or after a platinum-based regimen; measurable disease per RECIST v1.1; tumor sample available for evaluation of PD-L1 expression; had received ≤ 2 prior chemotherapy regimens; aged ≥ 18; ECOG PS of 0 or 1.